Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: The role of inadequate empirical antimicrobial therapy

Clinical Infectious Diseases

Volumn 41, Issue 7, 2005, Pages 923-929

  Lautenbach, Ebbing ^a   Metlay, Joshua P ^a,b   Bilker, Warren B ^a   Edelstein, Paul H ^a   Fishman, Neil O ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFEPIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; GENTAMICIN; LEVOFLOXACIN; NETILMICIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; CONTROLLED STUDY; EMPIRICAL ANTIMICROBIAL THERAPY; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE INFECTION; HOSPITAL PATIENT; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; THERAPY DELAY; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG UTILIZATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 25444451566     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/432940     Document Type: Article

References (36)

1. Hooper DC. New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis 2000; 30:243-54.
2. Pfaller MA, Jones RN, Doern GV, Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998; 42:1762-70.
3. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 2000; 30:454-60.
4. Livermore DM, James D, Reacher M, et al. Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg Infect Dis 2002; 8:473-8.
5. Lautenbach E, Strom BL, Nachamkin I, et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004; 38: 655-62.
6. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JR Antibiotic resistance among gram-negative bacilli in US intensive care units. JAMA 2003; 289:885-8.
7. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum B-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001; 33:1288-94.
8. Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum B-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000; 30:473-8.
9. Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Ann Intern Med 2001; 135:484-92.
10. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002; 162:2229-35.
11. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162-71.
12. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36:1433-7.
13. Vila J, Simon K, Ruiz J, et al. Are quinolone-resistant uropathogenic Escherichia coli less virulent? J Infect Dis 2002; 186:1039-42.
14. Blazquez R, Menasalvas A, Carpena I, Ramirez C, Guerrero C, Moreno S. Invasive disease caused by ciprofloxacin-resistant uropathogenic Escherichia coli. Eur J Clin Microbiol Infect Dis 1999; 18:503-5.
15. Lautenbach E, Fishman NO, Bilker WB, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002; 162:2469-77.
16. NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th ed. NCCLS document M7-A5. Wayne, PA: NCCLS, 2000.
17. Garner JS, Jarvis WR, Emori TG, Horau TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128-40.
18. Knaus WA, Drapier EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-29.
19. Lautenbach E, Schuster MG, Bilker WB, Brennan PJ. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis 1998; 27:1259-65.
20. Noskin GA, Peterson LR, Warren JR. Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. Clin Infect Dis 1995; 20:296-301.
21. Weinstein MP, Murphy JR, Reller LB, Lichtenstein KA. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II. Clinical observations, with special reference to factors influencing prognosis. Rev Infect Dis 1983; 5:54-70.
22. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. New York: Van Nostrand Reinhold, 1982.
23. Hosmer DO, Lemeshow SL. Applied logistic regression. New York: Wiley and Sons, 1989.
24. Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 1996; 49:907-16.
25. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989; 79:340-9.
26. Robins JM, Greenland S. The role of model selection in causal inference from nonexperimental data. Am J Epidemiol 1986; 123:392-402.
27. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993; 138:923-36.
28. Ortiz J, Vila MC, Soriano G, et al. Infections caused by Escherchia coli resistant to norfloxacin in hospitalized cirrhotic patients. Hepatology 1999; 29:1064-9.
29. Cheong HJ, Yoo CW, Sohn JW, Kim WJ, Kim MJ, Park SC. Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis 2001; 33:48-53.
30. Maslow JN, Lautenbach E, Bilker WB, Johnson JR. Colonization with extraintestinal pathogenic Escherichia coli among nursing home residents and its relationship to fluoroquinolone resistance. Antimicrob Agents Chemother 2004; 48:3618-20.
31. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-55.
32. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122:262-8.
33. Thomson KS, Sanders WE, Sanders CC. USA resistance patterns among UTI pathogens. J Antimicrob Chemother 1994;33(Suppl A):9-15.
34. Lee YL, Thrupp LD, Nathvogel S, Nassar J, Farad N, Cesario T. Infection surveillance and antibiotic utilization in a skilled nursing facility. Aging 1996; 8:113-22.
35. Richard P, Delangle MH, Merrien D, et al. Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clin Infect Dis 1994; 19:54-9.
36. Muder RR, Brennen C, Goetz AM, Wagener MM, Rihs JD. Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veteran's Affairs medical center. Antimicrob Agents Chemother 1991; 35:256-8.